Catalyst Event
Novartis AG (NVS) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
6/1/2026, 12:00:00 AM
New data for Cosentyx, ianalumab, and Scemblix to be presented at the EULAR and ASCO 2026 congresses on 2026-06-01, highlighting positive results in immunology and oncology scheduled. Medium importance is estimated as clinical data for key drugs typically drives a 5% market reaction scheduled.
Korean Translation
2026년 6월 1일 EULAR 및 ASCO 2026 학회에서 코센틱스, 이아날루맙, 셈블릭스에 대한 새로운 데이터를 발표하고 면역학 및 종양학 분야의 긍정적인 결과를 강조할 예정임. 주요 약물의 임상 데이터 발표는 통상적으로 5% 수준의 주가 변동을 야기하므로 'Medium'으로 예정됨.
Related Recent Events
Abbott Laboratories (ABT) · Earnings Release
Abbott's Q2 2026 earnings release is scheduled for July 16, 2026. Analysts forecast EPS of $1.28. Medium importance estimated as earnings typically drive >5% price movement expected.
7/16/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly cash dividend of $1.25 per share has an ex-dividend date of June 12, 2026. The dividend is scheduled to be paid on June 26, 2026.
6/12/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
New Phase 3 data for the pipeline drug CagriSema to be presented at the American Diabetes Association (ADA) Scientific Sessions on June 7, 2026, with a low price impact scheduled.
6/7/2026, 12:00:00 AM
Lululemon Athletica Inc (LULU) · Earnings Release
Lululemon Athletica is scheduled to release its financial results for the first quarter of fiscal 2026 on June 4, 2026, after the market closes. High importance is estimated as earnings releases typically result in significant price volatility. scheduled
6/4/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Other
RBC Capital analysts forecast a price target of $43.00 for Life Time Group Holdings on June 2, 2026; target increases typically suggest a low positive impact, forecasted.
6/2/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Other
Positive results from the EMERALD-3 Phase III trial were presented at the ASCO 2026 meeting on 2026-06-01, showing that Imfinzi and Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in patients with unresectable liver cancer; high market impact (>=10%) expected due to significant clinical efficacy.
6/1/2026, 12:00:00 AM